Cited by 40Nausea and vomiting managementCannabis and Cannabinoid ResearchGastrointestinal motility and disorders

Δ9-Tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew

Open access
Ray, Andrew P., Griggs, Lisa, Darmani, Nissar A.·2009·Behavioural Brain Research

Abstract

Cisplatin chemotherapy frequently causes severe vomiting in two temporally separated clusters of bouts dubbed the acute and delayed phases. Cannabinoids can inhibit the acute phase, albeit through a poorly understood mechanism. We examined the substrates of cannabinoid-mediated inhibition of both the emetic phases via immunolabeling for serotonin, Substance P, cannabinoid receptors 1 and 2 (CB(1), CB(2)), and the neuronal activation marker Fos in the least shrew (Cryptotis parva). Shrews were injected with cisplatin (10mg/kg i.p.), and one of vehicle, Delta(9)-THC, or both Delta(9)-THC and the CB(1) receptor antagonist SR141716A (2mg/kg i.p.), and monitored for vomiting. Delta(9)-THC-pretreatment caused concurrent decreases in the number of shrews expressing vomiting and Fos-immunoreactivity (Fos-IR), effects which were blocked by SR141716A-pretreatment. Acute phase vomiting induced Fos-IR in the solitary tract nucleus (NTS), dorsal motor nucleus of the vagus (DMNX), and area postrema (AP), whereas in the delayed phase Fos-IR was not induced in the AP at all, and was induced at lower levels in the other nuclei when compared to the acute phase. CB(1) receptor-IR in the NTS was dense, punctate labeling indicative of presynaptic elements, which surrounded Fos-expressing NTS neurons. CB(2) receptor-IR was not found in neuronal elements, but in vascular-appearing structures. All areas correlated with serotonin- and Substance P-IR. These results support published acute phase data in other species, and are the first describing Fos-IR following delayed phase emesis. The data suggest overlapping but separate mechanisms are invoked for each phase, which are sensitive to antiemetic effects of Delta(9)-THC mediated by CB(1) receptors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbr.2008.07.028

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 41 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [10]Darmani NA Gerdes D Trinh C Structurally Diverse Cannabinoids Prevent Substance P-Induced Emesis via Cannabinoid CB1 Receptor in Cryptotis Parva The 15th Annual Symposium on the Cannabinoids P56 Clearwater Beach, Florida 2005

Cited by

Sorted by citations

Authors
Ray, A. P., Griggs, L., & Darmani, N. A.
Affiliations
Western University of Health Sciences (US)
Corresponding author
Darmani, Nissar A.
Venue
Behavioural Brain Research
Publisher
Elsevier BV
Published
2009-01
Volume
196
Issue
1
Pages
30-36
ISSN
0166-4328 (ISSN-L)
OpenAlex
W2047463238
Cited by
40
References
41
Citations by year
2025: 1 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 5 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 1
FWCI
4.58
Type
journal article
Language
en
Open access
Locations
  • Behavioural Brain Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (R01CA115331)
Topics
  • Health Sciences › Medicine › Surgery › Nausea and vomiting management
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
delta-9-tetrahydrocannabinol, cisplatin-induced emesis, chemotherapy-induced vomiting, Fos expression, CB1 receptor, CB2 receptor, SR141716A, solitary tract nucleus, dorsal motor nucleus of the vagus, area postrema, serotonin, substance P, least shrew
MeSH terms
Rimonabant, Animals, Brain Stem, Cisplatin, Drug Therapy, Combination, Female, Immunohistochemistry, Injections, Intraperitoneal, Neurons, Piperidines, Pyrazoles, Serotonin, Shrews, Substance P, Dronabinol, Time Factors, Vomiting, Oncogene Proteins v-fos, Solitary Nucleus, Presynaptic Terminals, Microscopy, Confocal, Analgesics, Non-Narcotic, Area Postrema, Receptor, Cannabinoid, CB1, Receptor, Cannabinoid, CB2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review